Scarica l'app Stockscreener
166.44
1.63%
-2.75
Dopo l'orario di chiusura:
166.44
Precedente Chiudi:
$169.19
Aprire:
$167.63
Volume 24 ore:
1.13M
Relative Volume:
0.73
Capitalizzazione di mercato:
$13.44B
Reddito:
$8.19B
Utile/perdita netta:
$758.19M
Rapporto P/E:
18.13
EPS:
9.18
Flusso di cassa netto:
$1.06B
1 W Prestazione:
-11.00%
1M Prestazione:
+11.79%
6M Prestazione:
-16.40%
1 anno Prestazione:
-49.12%
Intervallo 1D:
$162.99
$169.00
Intervallo di 1 settimana:
$162.99
$190.56
Portata 52W:
$125.10
$328.35
Icon Plc Stock (ICLR) Company Profile
Nome
Icon Plc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ICLR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
166.44 | 13.16B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
463.04 | 176.55B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.09 | 141.18B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
535.54 | 42.97B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.50 | 32.61B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
182.45 | 31.60B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Downgrade | TD Cowen | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Iniziato | Redburn Atlantic | Neutral |
| 2024-09-18 | Iniziato | Leerink Partners | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2023-12-15 | Iniziato | Truist | Buy |
| 2023-09-13 | Iniziato | TD Cowen | Outperform |
| 2023-01-17 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-09-07 | Iniziato | UBS | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-14 | Iniziato | Citigroup | Neutral |
| 2021-04-13 | Ripresa | BofA Securities | Neutral |
| 2021-04-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Iniziato | Barclays | Equal Weight |
| 2021-03-01 | Aggiornamento | UBS | Neutral → Buy |
| 2021-02-26 | Aggiornamento | Truist | Hold → Buy |
| 2020-07-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Hold |
| 2020-01-27 | Downgrade | SunTrust | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-09-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Aggiornamento | UBS | Sell → Neutral |
| 2019-01-25 | Aggiornamento | Mizuho | Neutral → Buy |
| 2018-10-26 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Iniziato | UBS | Sell |
| 2018-04-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Reiterato | Mizuho | Neutral |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
| 2017-10-27 | Reiterato | Barclays | Equal Weight |
| 2017-09-11 | Iniziato | BofA/Merrill | Buy |
| 2017-07-31 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-27 | Reiterato | Mizuho | Neutral |
| 2017-06-29 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Icon Plc Borsa (ICLR) Ultime notizie
Fund Update: First Pacific Advisors, LP added 417,173 shares of ICON PLC ($ICLR) to their portfolio - Quiver Quantitative
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
ICON's Intrinsic Value Estimated at $278, 33% Undervalued by Current Share Price - AInvest
Icon price target raised to $225 from $173 at Mizuho - TipRanks
Icon PLC (ICLR) Q2 Report: Barclays Raises Price Target to $180, Maintains Equal Weight Rating - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON Stock Surge: Future Safe or Risky? - StocksToTrade
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Growth or Bubble? Decoding the Rapid Rise of ICLR Stock - StocksToTrade
Icon PLC Q2 Earnings Exceed Projections with $183 Million ProfitNews and Statistics - IndexBox
S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's
ICON: Lower Guidance Downside & Expanded Repurchase Plan (ICLR) - Seeking Alpha
Icon PLC: Q2 Earnings Snapshot - CTPost
ICON Announces Results of Annual General Meeting - BioSpace
ICON PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
ICON plc Reports Strong Q2 2025 Financial Results and Updates Guidance - TipRanks
ICON PLC earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
SUI Insider Grant: President Gets 4,788 Restricted Shares at $125.06 | ICLR SEC FilingForm 6-K - Stock Titan
ICON Reports Second Quarter 2025 Results | ICLR Stock News - GuruFocus
ICON's Resilience in a Turbulent Market: A Case for Strategic Investment - AInvest
ICON Announces Results of Annual General Meeting | ICLR Stock News - GuruFocus
ICON Clinical Research Earnings Soar 31% as Business Wins Hit $3B, Expands $1B Buyback Program - Stock Titan
ICON plc Stock Takes Center Stage. What’s Next? - StocksToTrade
ICON plc’s Market Surge: Examining Strong Moves - timothysykes.com
ICON plc Emerges as Phase 1 Clinical Trials Leader in New Benchmark Report - StocksToTrade
ICON plc Emerges as Top Contender in Clinical Research Arena - timothysykes.com
Icon (ICLR) Shares Surge Over 14% to Reach $160 | ICLR Stock New - GuruFocus
ICON PLC expected to post earnings of $3.21 a shareEarnings Preview - TradingView
Icon ICLR 2025Q2 Earnings Preview Downside Risk Amid Macroeconomic Issues and Trial Delays - AInvest
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for - MSN
ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly - 富途牛牛
Medical Device Regulatory Affairs Market Key Players Analysis - openPR.com
Do You Believe in the Upside Potential of ICON PLC (ICLR)? - MSN
Launch Your Career as a Life Science Intern at ICON, Apply Now! - BioTecNika
Icon Plc Azioni (ICLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.54%
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):